SenesTech Announces 2022 Financial Results
PHOENIX, March 16, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, ContraPest®, today announced 2022 financial results, with products sales increasing 77% compared to the prior year.
- PHOENIX, March 16, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), ( www.senestech.com ) the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, ContraPest®, today announced 2022 financial results, with products sales increasing 77% compared to the prior year.
- We are focused on taking the foundation built in 2022 and accelerating beyond the current growth rates," added Mr. Fruendt.
- Adjusted EBITDA loss, which is a non-GAAP measure of operating performance, for 2022 was $8.5 million compared to $7.8 million in 2021.
- Net loss during Q4 2022 was $2.1 million, compared with a net loss of $2.5 million for Q4 2021.